title: Pulmonary pathology of patients treated with partial liquid ventilation.
abstract: Initial trials of partial liquid ventilation (PLV), which is gas ventilation of perfluorocarbon-filled lungs, are underway in patients with severe respiratory failure. We report the first study of the effects of the perfluorocarbon, perflubron, on the lung. Necropsies were conducted in nine patients (seven adults and two neonates; mean adult age, 31 +/- 5 yr) managed with PLV (average number of doses, 4 +/- 1). All of the patients required extracorporeal life support. The patients had pneumonia with the acute respiratory distress syndrome (six patients), trauma/capillary leak syndrome (one patient), congenital diaphragmatic hernia (one patient), and primary pulmonary hypertension (one patient). Nine adult patients (mean age, 37 +/- 5 yr) with acute respiratory distress syndrome requiring extracorporeal life support served as a control. Pathologic findings were evaluated in both groups. Lung weights in the adult patients of both groups were elevated (mean weight of PLV-treated right lung, 1401 +/- 186 g; mean weight of PLV-treated left lung, 1131 +/- 177 g; mean weight of control right lung, 1018 +/- 91 g; mean weight of control left lung, 988 +/- 80 g). There was no significant difference between the two groups (right lung, P = .066; left lung, P = .436). Frequent gross findings included focal consolidation, patchy hemorrhage, and glassy cut surfaces. The histologic findings were similar in both groups. Diffuse alveolar damage (either proliferative phase or mixed proliferative and exudative phases) was seen in all nine of the study patients. Eight of the nine control patients had diffuse alveolar damage (five had proliferative phase only, one had mixed proliferative and exudative phases, and two had exudative phase only). One other patient had extensive parenchymal necrosis. Other frequent findings were intra-alveolar hemorrhage, numerous intra-alveolar macrophages, and organization of exudate. PLV with perflubron in patients with adult and neonatal respiratory distress syndromes is not associated with unique pathologic findings in the human lung.
authors.affiliation: Department of Pathology, University of Michigan Hospitals, Ann Arbor 48109-0054, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Bruch
authors.forename: A
authors.initials: A
authors.lastname: Flint
authors.forename: R B
authors.initials: RB
authors.lastname: Hirschl
mesh_terms: D000280:Administration, Inhalation; D000328:Adult; D005260:Female; D005466:Fluorocarbons / Q000009:adverse effects*; D006801:Humans; D006842:Hydrocarbons, Brominated; D007223:Infant; D007231:Infant, Newborn; D008168:Lung / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D012123:Pulmonary Ventilation / Q000187:drug effects; D012121:Respiration, Artificial / Q000009:adverse effects* / Q000379:methods; D012131:Respiratory Insufficiency / Q000473:pathology* / Q000628:therapy
chemical_list: D005466:Fluorocarbons; D006842:Hydrocarbons, Brominated; C003072:perflubron